by Kall Kwik WGC | Apr 29, 2016 | Free Library
April, 2016 SMM-142 GSK’s Morality Gene GSK’s recent decisions about pricing, transparency and return on investment seem to indicate an interesting new adaption to market conditions, one that is likely to be followed by the industry. This...
by Kall Kwik WGC | Mar 23, 2016 | Free Library
March, 2016 SMM-141 Sexual selection By focusing on a particular trait when we interview candidates for a position in our organisation, we may open ourselves up to unintended consequences, neglecting the full range of routines we...
by Kall Kwik WGC | Mar 9, 2016 | Free Library
February, 2016 SMM-140 Under Pressure There are six inexorable forces shaping the evolution of pharma and medtech. Asking and answering the questions about what selection pressures are acting in our industry is the first step in predicting how...
by Kall Kwik WGC | Mar 9, 2016 | Free Library
February, 2016 SMM-139 J&J’s Portent of Purity There is a new pattern of shareholder pressure across the sector, leading to new corporate structures being seen to emerge.
by Kall Kwik WGC | Jan 26, 2016 | Free Library
January, 2016 SMM-138 Not as we know it When it comes to evolution in industry, we need to think bout how the patient need will be met in future and evolve accordingly.
by Kall Kwik WGC | Jan 6, 2016 | Free Library
December, 2015 SMM-137 The Future of Pfizer(s) The media is full of the Pfizer-Allergan deal, especially the likely break up of the post-merger company into ‘innovative’ and ‘mature’ products. But lacking in this frenzied coverage is any sort of...
